Table 5.
Omega-3 fatty acid supplements and pharmaceuticals
PRODUCT | FORMULATION | ORIGIN AND AVAILABILITY |
---|---|---|
Nonprescription26,75 | ||
|
|
Multiple ratios and concentrations |
|
|
Multiple products |
|
|
|
Prescription only76 | ||
|
|
|
|
|
|
|
|
|
DHA—docosahexaenoic acid, EPA—eicosapentaenoic acid, REDUCE-IT—Reduction of Cardiovascular Events with EPA-Intervention Trial, STRENGTH—Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia.